| Pharmaceutical Quality/Chemistry, Manufacturing, and Controls (CMC) |
Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry |
Final |
1/23/2023 |
| Clinical - Medical |
Mpox: Development of Drugs and Biological Products |
Draft |
1/19/2023 |
| Labeling |
Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format |
Draft |
1/12/2023 |
| Drug Safety |
Format and Content of a REMS Document |
Final |
1/4/2023 |
| ICH - Multidisciplinary |
M11 Template: Clinical Electronic Structured Harmonised Protocol |
Draft |
12/21/2022 |
| ICH - Multidisciplinary |
M11 Technical Specification: Clinical Electronic Structured Harmonised Protocol |
Draft |
12/21/2022 |
| ICH - Multidisciplinary |
M11 Clinical Electronic Structured Harmonised Protocol |
Draft |
12/21/2022 |
| Generic Drugs |
Controlled Correspondence Related to Generic Drug Development |
Draft |
12/21/2022 |
| Labeling |
Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims |
Final |
12/15/2022 |
| Clinical-Antimicrobial |
Pulmonary Tuberculosis: Developing Drugs for Treatment |
Draft |
12/14/2022 |
| Generics |
Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry |
Final |
12/14/2022 |
| Compliance |
Drug Products Labeled as Homeopathic Guidance for FDA Staff and Industry |
Final |
12/7/2022 |
| Clinical - Medical |
Small Volume Parenteral Drug Products and Pharmacy Bulk Packages for Parenteral Nutrition: Aluminum Content and Labeling Recommendations |
Draft |
12/6/2022 |
| ICH-Safety |
E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials |
Final |
12/5/2022 |
| Generics |
Statistical Approaches to Establishing Bioequivalence |
Draft |
12/2/2022 |
| Generics |
ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions |
Draft |
12/2/2022 |
| Clinical-Antimicrobial |
Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food, Drug, and Cosmetic Act |
Final |
11/18/2022 |
| ICH-Quality |
Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin |
Draft |
11/10/2022 |
| Generics |
Sameness Evaluations in an ANDA — Active Ingredients |
Draft |
11/8/2022 |
| Clinical - Medical |
M10 Bioanalytical Method Validation and Study Sample Analysis |
Final |
11/4/2022 |
| Clinical - Medical |
Cross Labeling Oncology Drugs in Combination Regimens |
Final |
11/2/2022 |
| ICH-Safety |
S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals |
Final |
11/2/2022 |
| User Fees |
Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program |
Draft |
11/1/2022 |
| Clinical - Medical |
Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials |
Draft |
10/31/2022 |
| Clinical - Antimicrobial |
Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention |
Draft |
10/27/2022 |
| Administrative/Procedural |
Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products |
Final |
10/27/2022 |
| Generics |
Topical Dermatologic Corticosteroids: In Vivo Bioequivalence |
Draft |
10/21/2022 |
| Generics |
In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs |
Draft |
10/21/2022 |
| Generics |
In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs |
Draft |
10/21/2022 |
| Generics |
Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs |
Draft |
10/21/2022 |
| Biostatistics |
Multiple Endpoints in Clinical Trials |
Final |
10/20/2022 |
| Clinical - Medical |
Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA |
Final |
10/13/2022 |
| Generics |
Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA |
Final |
10/5/2022 |
| Generics |
Competitive Generic Therapies |
Final |
10/5/2022 |
| Generics |
Facility Readiness: Goal Date Decisions Under GDUFA |
Draft |
10/3/2022 |
| Pharmaceutical Quality/Chemistry, Manufacturing, and Controls (CMC) |
Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA |
Draft |
10/3/2022 |
| Pharmaceutical Quality/Chemistry, Manufacturing, and Controls (CMC) |
Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules |
Final |
10/3/2022 |
| Electronic Submissions |
Providing Over-the-Counter Monograph Submissions in Electronic Format |
Draft |
9/27/2022 |
| Administrative/Procedural |
Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry |
Final |
9/22/2022 |
| Administrative/Procedural |
How To Obtain a Covered Product Authorization |
Draft |
9/21/2022 |
| Labeling |
Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products |
Draft |
9/8/2022 |
| Labeling |
Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products |
Draft |
9/8/2022 |
Real World Data/Real World Evidence (RWD/RWE)
Administrative/Procedural |
Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products |
Final |
9/8/2022 |
| |
E11A Pediatric Extrapolation |
Draft |
8/26/2022 |
| ICH-Multidisciplinary |
M12 Drug Interaction Studies |
Draft |
8/26/2022 |
| ICH-Quality |
Q14 Analytical Procedure Development |
Draft |
8/26/2022 |
| ICH-Quality |
Q2(R2) Validation of Analytical ProceduresQ14 Analytical Procedure Development |
Draft |
8/26/2022 |
| ICH-Efficacy, ICH-Safety |
E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers |
Final |
8/26/2022 |
|
|
| Generics |
In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs |
Draft |
10/21/2022 |
| Generics |
In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs |
Draft |
10/21/2022 |
| Generics |
Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs |
Draft |
10/21/2022 |
| Biostatistics |
Multiple Endpoints in Clinical Trials |
Final |
10/20/2022 |
| Clinical - Medical |
Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA |
Final |
10/13/2022 |
| Generics |
Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA |
Final |
10/5/2022 |
| Generics |
Competitive Generic Therapies |
Final |
10/5/2022 |
| Generics |
Facility Readiness: Goal Date Decisions Under GDUFA |
Draft |
10/3/2022 |
| Pharmaceutical Quality/Chemistry, Manufacturing, and Controls (CMC) |
Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA |
Draft |
10/3/2022 |
| Pharmaceutical Quality/Chemistry, Manufacturing, and Controls (CMC) |
Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules |
Final |
10/3/2022 |
| Electronic Submissions |
Providing Over-the-Counter Monograph Submissions in Electronic Format |
Draft |
9/27/2022 |
| Administrative/Procedural |
Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry |
Final |
9/22/2022 |
| Administrative/Procedural |
How To Obtain a Covered Product Authorization |
Draft |
9/21/2022 |
| Labeling |
Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products |
Draft |
9/8/2022 |
| Labeling |
Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products |
Draft |
9/8/2022 |
Real World Data/Real World Evidence (RWD/RWE)
Administrative/Procedural |
Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products |
Final |
9/8/2022 |
| |
E11A Pediatric Extrapolation |
Draft |
8/26/2022 |
| ICH-Multidisciplinary |
M12 Drug Interaction Studies |
Draft |
8/26/2022 |
